From the publisher feed
The White House’s abrupt withdrawal of Heidi Overton as President Trump’s nominee to lead the Food and Drug Administration (FDA) means the agency will remain without stable leadership six months after the former commissioner resigned, leaving industry observers anxious. The Trump administration’s last-minute pulling of Overton’s nomination caught senators by surprise this week. Sen. Bill
Read the original at The Hill ↗Opens the original publisher page. Access, copyright and subscriptions are controlled by the publisher.
A useful next step
- Read the short publisher description here.
- Open the full report directly at the publisher.
- Compare this topic with other sources when useful.